OrbiMed Closes $3 Billion Across Two New Funds, Splitting Its Firepower Between West and Asia

OrbiMed has closed two new private equity funds totaling $3 billion, allocating capital to life sciences in the US and Europe, and healthcare across Asia. The firm's investment strategy is shaped by AI, new therapeutic modalities, and the growth of China's biotechnology industry.

Rafael Montoya

October 16, 2026 · 3 min read

OrbiMed has raised $3 billion in commitments across two new private equity funds, the healthcare-focused investment firm announced on October 15, 2026. The close pairs OrbiMed Private Investments X, which gathered more than $1.9 billion for life sciences venture capital in the US and Europe, with OrbiMed Asia Partners VI, which raised more than $1 billion for healthcare venture and growth equity across Asia.

OrbiMed Secures $3 Billion for New Life Sciences and Healthcare Funds

The double close marks one of the largest healthcare fundraising events of the year. OrbiMed Private Investments X carries the larger mandate, with over $1.9 billion in commitments directed at venture-stage life sciences companies on both sides of the Atlantic. OrbiMed Asia Partners VI, at more than $1 billion, is the firm's latest vehicle for Asian healthcare opportunities and combines venture capital with growth equity exposure.

Both funds share a common sectoral lens. According to reports on the announcement, each will target biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. The parallel mandates suggest OrbiMed views these four segments as the core of healthcare's investable frontier, regardless of geography, while using separate vehicles to tailor capital deployment to regional market conditions.

The firm manages more than $21 billion across its global healthcare investment platform, meaning the new commitments represent a substantial but not transformative addition to assets under management. For life sciences and healthcare companies in the US, Europe, and Asia seeking venture or growth capital, the close signals a deep, freshly funded pool of dedicated healthcare capital.

Reported characteristics of OrbiMed's two funds closed in October 2026
Dimension	OrbiMed Private Investments X	OrbiMed Asia Partners VI
Capital raised	More than $1.9 billion	More than $1 billion
Geographic focus	US and Europe	Asia
Investment type	Venture capital	Venture capital and growth equity
Target sectors	Biopharmaceuticals, medical devices, diagnostics, technology-enabled healthcare services	Biopharmaceuticals, medical devices, diagnostics, technology-enabled healthcare services

Comparing 2026 and 2021 Fundraises: An Evolving Strategy

The close invites comparison with OrbiMed's previous flagship effort. In March 2021, the firm announced $3.5 billion raised across three funds, covering North America and Europe, Asia, and royalty and credit opportunities, according to OrbiMed's own announcement at the time.

The 2026 raise is smaller in aggregate but consolidated into two vehicles. The most visible structural shift is the apparent absence of a dedicated royalty and credit fund in the new lineup, concentrating the firm's fresh capital on equity investments in operating companies. The geographic architecture, by contrast, is continuous: a Western life sciences fund paired with an Asia-focused healthcare fund, echoing the 2021 structure.

The continuity of the Asia franchise is notable. OrbiMed has now raised successive Asia-focused funds roughly five years apart, a cadence that reflects both the depth of its limited partner relationships and its conviction in Asian healthcare markets, particularly China's biotech sector as Gordon emphasized.

One caveat applies throughout: details of the 2026 funds come from secondary reporting on the announcement, and the firm has not disclosed the limited partners backing either vehicle. The 2021 figures, by contrast, come from OrbiMed's own press release, so the comparison rests on differently sourced baselines.